Non-small Cell Lung Cancer Clinical Trials in Shanghai, Shanghai Municipality
48 recruitingShanghai, Shanghai Municipality, China
Showing 1–20 of 48 trials
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC614 enrolled218 locationsNCT06170788
Recruiting
Phase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC600 enrolled215 locationsNCT06345729
Recruiting
Phase 2Phase 3
A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb590 enrolled264 locationsNCT07063745
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Endometrial CancerPrimary Peritoneal CarcinomaNon-small Cell Lung Cancer+6 more
Genmab764 enrolled66 locationsNCT05579366
Recruiting
Phase 2Phase 3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung Cancer
Mirati Therapeutics Inc.806 enrolled764 locationsNCT04613596
Recruiting
Phase 1
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
MelanomaNon-small Cell Lung CancerRenal Cell Carcinoma
Shanghai Henlius Biotech174 enrolled69 locationsNCT07160335
Recruiting
Phase 1
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors
Non-small Cell Lung CancerSolid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.20 enrolled1 locationNCT06612840
Recruiting
Phase 1
A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations
NSCLC (Advanced Non-small Cell Lung Cancer)
Tongji University36 enrolled1 locationNCT07361237
Recruiting
Phase 1Phase 2
Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd50 enrolled1 locationNCT06903377
Recruiting
Phase 1
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
Non-small Cell Lung CancerSolid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.31 enrolled1 locationNCT07056556
Recruiting
Phase 2
Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Shanghai Proton and Heavy Ion Center43 enrolled1 locationNCT05613452
Recruiting
Phase 2
Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients
Radiotherapy Side EffectNon-small Cell Lung CancerOlder People+1 more
Jian Chen29 enrolled1 locationNCT06311981
Recruiting
Phase 1Phase 2
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
Non-small Cell Lung Cancer (NSCLC)
Suzhou Suncadia Biopharmaceuticals Co., Ltd.400 enrolled1 locationNCT06754930
Recruiting
Phase 1Phase 2
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Non-small Cell Lung CancerKRAS P.G12C
Allist Pharmaceuticals, Inc.240 enrolled27 locationsNCT05288205
Recruiting
Not Applicable
GT201 Injection in Combination with Teraplizumab Injection for Treatment of Patients with Non-small Cell Lung Cancer
Non-small Cell Lung CancerAdult
Grit Biotechnology20 enrolled3 locationsNCT06235242
Recruiting
Phase 2
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
Non-Small Cell Lung Cancer With EGFR Mutation
Abbisko Therapeutics Co, Ltd54 enrolled5 locationsNCT06668103
Recruiting
Phase 1
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
Non-small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd.250 enrolled5 locationsNCT06403735
Recruiting
Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC
Non-small Cell Lung CancerNeuroendocrine CarcinomaHistology Transformation
Fudan University50 enrolled1 locationNCT06369181
Recruiting
Survival Validation and Gene Mutations of N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer
Non-small Cell Lung Cancer
Fudan University1,263 enrolled1 locationNCT06349252
Recruiting
Phase 3
SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
Non-small Cell Lung Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd.242 enrolled1 locationNCT06080776